<DOC>
	<DOCNO>NCT00162500</DOCNO>
	<brief_summary>Rationale : ImMucin show able induce robust cellular immune response mediate via CD4+ CD8+ T lymphocytes therefore , could potentially effective majority target population . Purpose : The purpose study evaluate safety initial efficacy ImMucin , novel peptide vaccine metastatic tumor express MUC-1 Tumor Associated Antigen ( TAA ) .</brief_summary>
	<brief_title>A Novel Vaccine Treatment MUC1-expressing Tumor Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>All patient must histological cytological diagnosis metastatic disease express MUC1 . Patients must metastatic disease fail least one regimen standard base chemotherapy metastatic disease : Renal Cell Carcinoma ( RCC ) , Transitional Cell Carcinoma ( TCC ) , Prostate , Breast , Ovary , Nonsmall cell lung , Colon , Multiple myeloma Pancreatic . Patients must &gt; 18 year age , consent participation study . Patients must least one site measurable tumor measurable tumor marker . Patients receive immunosuppressive treatment could negate development effective immune response vaccine . Subjects prior irradiation field include 25 % lymph node bone marrow likely immunosuppressed exclude . However , patient standard pelvic field radiation adjuvant therapy rectal cancer exclude . Pregnant breast feed woman exclude . Premenopausal woman practice willing practice adequate birth control method period 3 month treatment exclude . Patients brain metastasis . Patients active infection . Patients HIV hepatitis B surface antigen ( HBS Ag ) hepatitis C virus ( HCV ) positive patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Metastatic solid tumor</keyword>
</DOC>